Breast cancer patients in England and Wales will not have access to the drug after pricing negotiations failed between NICE and drugmakers.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.

The firm is paying €7 million to add fibroblast activation protein-targeting assets to its pipeline, which it will initially develop for bladder cancer.

The company expects the trial to support the submission of a biologics license application with the US Food and Drug Administration in 2026.

In the trial, researchers will test how well Medera's SRD-001 gene therapy improves symptoms in heart failure patients with reduced ejection fraction.

NEW YORK – Apeiron Therapeutics on Tuesday said it enrolled the first patient with MTAP-deleted advanced cancer in a Phase Ia/b trial testing the activity of its PRMT5 inhibitor GTA182. In the ...